1 Spectroscopy techniques are valuable tools in biomedical research and have been used 2 extensively in the study of disease. However, neurological conditions such as multiple 3 sclerosis (MS) have received little attention and the available spectroscopy studies are 4 limited, both in overall numbers of patients studied and the disease samples considered. MS 5 is a complex immune-mediated disease, with variable clinical courses and limited 6 therapeutic options. This review aims to summarize current literature in the area, 7 demonstrating how spectroscopy techniques can provide valuable information to inform and 8 advance research into the most common neurological condition affecting young adults. 9
Introduction

10
Biophotonic techniques are now widely used in biomedical research targeting better 11 diagnosis, prognosis and surveillance of disease. Vibrational spectroscopy methods such as 12 Fourier-transform infrared (FTIR) and Raman spectroscopy are so called because they 13 probe the intramolecular vibrations and rotations of a sample when irradiated with a light 14 source (1). The vibrational energy levels can be probed by both techniques, using different 15 physical processes. Raman spectroscopy studies the Raman effect, the spontaneous 16 inelastic light scattering process of photons, following the interaction of monochromatic 17 radiation (e.g. a laser) with the sample. In contrast, FTIR spectroscopy studies the samples' 18 absorption characteristics arising from the molecular motion due to atomic displacement 19 upon interaction with an infrared source (2, 3). In both cases, the recording of vibrational 20 energy level transactions results in a spectrum composed of peaks/bands that can be 21 interpreted qualitatively (peak position) and quantitatively (peak intensity/area) (4). In FTIR 22 spectroscopy, the spectral bands arise from a change in the electric dipole moment of the 23 molecules, whereas in Raman spectroscopy, they arise from a change in molecular 24 polarizability. FTIR and Raman spectroscopies are therefore complementary and provide a 25 "fingerprint" or "signature" of the specific molecules contained within a biological sample 26 (proteins, lipids, DNA) , depending upon whether their bonds exhibit infrared or Raman 27 activities. Both FTIR and Raman can be used for imaging tissue sections and are non-28 destructive, label-free techniques with sub-micron spatial resolution (5).
29
In biomedical research, scientists are continually investigating and exploring the application 30 of new technologies that can detect early signs of disease and thereby reduce disease 31 morbidity and mortality. The detection of biomarkers plays an important role in this 32 exploration. In oncology, such biomarkers, have been used extensively to determine risk 33 factors, aid diagnosis and prognosis, and in the assessment of treatment response as well 34 as determining disease recurrence (4). However, from amongst the vast numbers of 35 candidate biomarkers, only a limited few have been validated for clinical use. Vibrational 36 spectroscopy is new investigatory tool in biomarker (re)search which is not restricted to the 37 analysis of a specific protein, nucleic acid and/or lipid. As such, FTIR and Raman spectra 38 are able to give spectral "signatures" or "biomarkers" which reflect the overall molecular 39 composition of the studied samples (4). 
45
MS is considered to be an autoimmune, neuro-inflammatory and degenerative condition, 46 which affects both the brain and spinal cord. Its precise aetiology remains unknown, 47 although both genetic and environmental factors influence an individual's susceptibility to 48 develop MS (9). The clinical course of this disease is variable but is divided into several 49 categories reflecting the degree of clinical disease activity and disability progression rate, 50 including relapsing remitting (RRMS), primary progressive (PPMS) and secondary 51 progressive MS (SPMS) (10). Whilst the inflammatory component of MS pathogenesis is 52 relatively well understood, the progressive neurodegenerative component of the disease, in 53 both its primary and secondary progressive clinical courses, is yet to be elucidated. In 54 PPMS, patients have a gradual and progressive decline in function from the outset, with 55 minimal disease activity detectable on magnetic resonance imaging (MRI) whereas in 56 SPMS, the gradual progression follows an initial relapsing remitting phase, usually over 57 many years (11). The consensus is that MS is a spectrum of conditions with RRMS being 58 one end of that spectrum and PPMS being at the other.
59
The key pathological features observed in MS are the influx of inflammatory immune cells 60 across the blood brain barrier into the CNS which results in the loss of axons and their 61 insulating myelin sheaths and the formation of lesions (plaques) in the white matter (WM) 62 and to a lesser extent in the grey matter (12). This process results in the impairment of 63 conduction along the affected axon leading to variable symptoms experienced by affected 64 patients including cognitive impairment, visual disturbances, sensory and motor symptoms, 65 impaired balance, sphincter disturbance and fatigue (13). Histopathological comparisons of 66 CNS tissue shows that the classical perivascular inflammation seen in SPMS is much less 67 prominent in PPMS and that more diffuse inflammatory changes and greater extent of 68 axonal damage in the normal appearing white matter (NAWM) are seen in PPMS (14, 15) . In 69 addition, there is evidence that patients with PPMS have a reduced capacity for re-70 myelination (11). Understanding the underlying pathogenesis which underpins the clinical 71 progression in MS at the molecular and cellular levels is therefore vital for the development 72 of therapies targeting the neurodegenerative process and enhancing remyelination 73 strategies.
74
The diagnosis of MS is usually based on the clinical presentation and the results of brain and 75 spinal MRI, which reveals evidence of active and chronic lesions as well as focal and 76 generalised atrophy (16). Current treatments for MS target the initial relapsing phase of the 77 disease, by preventing inflammatory responses leading to a reduction in the number and 78 severity of relapses (17). However, there are currently no treatments for primary and 79 5 secondary progressive MS although two therapeutic agents are waiting to be licenced (18). .
80
The underlying pathogenesis of the initial inflammatory phase of MS has been well 81 characterised at both the cellular and molecular level. However the pathogenesis of the 82 progressive phase is still not fully elucidated, although changes in the NAWM appear to be 83 pivotal (12). The progressive loss of axons seem to continues despite the reduction of further drawback of these animal models is that off the multitude of therapies found to be 104 effective in preventing EAE, a very small number have been taken forward into clinical trials 105 (23), suggesting that the models do not fully mimic the pathogenesis of MS in humans.
106
Current research approaches to investigating the aetiology of MS focus on the search for 107 specific genes/proteins/lipids that are thought to be involved in the disease process using a 108 variety of cell and molecular biology approaches. More recently DNA microarrays have been (28). This rapid communication reported that it was possible 124 to discriminate between different types of MS tissue attributed to variations in intrinsic lipid 125 and water content. Whilst FTIR spectra of white matter was dominated by lipids and protein 126 absorptions and grey matter spectra showed reduced lipid content alongside an increase 127 contribution of water to the spectra; MS lesion spectra were suggestive of both lipid and 128 water depletion, as would be expected from histopathological tissue analysis (28).
129
Differences comparing white and grey matter as well as white matter with MS lesions were 130 most notable in the 2800-3000 cm -1 spectral region, where most infrared bands arise from 131 CH 2 and CH 3 stretching vibrations of lipid acyl chains. Four main assignments were made to 132 CH 3 and CH 2 asymmetric stretching vibrations at 2956 and 2922 cm -1 and, to symmetric 133 vibrations at 2871 and 2851 cm -1 respectively. The overall intensity of these peaks were 134 reduced in both grey matter and MS lesion tissue, compared to normal control white matter, 135 which the authors explained was due to the expected lower lipid content of grey matter and 136 MS lesions, due to demyelination. Similarly, the CH 2 /CH 3 ratio is also decreased as a 137 decrease in lipid to protein ratio leads to methylene and methyl groups of amino-acid side 138 chains dominating this spectral region; as the CH 2 /CH 3 ratio in proteins is much lower than in 139 lipids, it was expected that the overall ratio would be decreased and band broadening would 140 be observed. In order to distinguish between grey matter and MS lesion tissue, the authors 141 reported the spectral region of 1200-1800 cm -1 to be most useful (28).
142
The main feature in white matter' spectra was observed at 1467 cm -1 and assigned to the 143 scissoring vibration of CH 2 groups of lipid acyl chains. In grey matter, the intensity absorption 144 of this CH 2 scissoring is reduced and is almost equal to the CH 3 asymmetric bending 145 vibrations at 1456 cm -1 . This is explained by the reduction in lipid content, which is also 7 apparent by the decrease in intensity of the terminal methyl groups of lipid chains and of the 147 (CH 3 ) 3 N + symmetric bending of phosphatidylcholine headgroups, assigned to the bands at 148 1381 and 1415 cm -1 , respectively. In contrast the COOsymmetric stretching band at 1400 149 cm -1 is increased in the spectra of grey matter in comparison to white matter. The same was 150 also observed at 1308 cm -1 which the authors assigned to amide III(28).
151
The spectral features of MS plaque tissue are similar to the ones described for grey matter.
152
Nevertheless, the intensity of CH 2 scissoring (1467 cm -1 ) to CH 3 asymmetric bending 153 vibrations (1456 cm -1 ) is now reversed with CH 3 asymmetric bending vibrations being the 154 main feature in this region. Similarly, the PO 2 antisymmetric stretching band also displays 155 greater intensity in the plaques' spectra comparatively to grey matter. Both these 156 observations were suggested to indicate that lipid content of MS plaques is lower than that of 157 the grey matter (28), which is known to be the case from histopathology studies (13).
158
In the 1500 to 11800 cm -1 spectral range the main feature observed was the amide I band 159 which arises from the C=O stretching vibration of amide groups of proteins and is centred at 160 1653 cm -1 . Other absorptions reported were assigned to C-C stretching of tyrosine at 1517 
189
It was concluded that the higher carbonyl to CH 2 ratio detected in the spectra of MS cases is 
213
Triplicate images were also acquired from an area furthest away from the lesion site, 214 referred to as "true NAWM" and from matched brain regions in tissue sections from control 215 9 non-MS cases. The average "true NAWM" spectra did not overlap with region-matched 216 control spectra, suggesting possible underlying pathology in MS tissue, which is not 217 differentiated when using lipophilic histochemistry or immunostaining with conventional 218 techniques (31).
219
The three major features in the CH spectral region analysed, correspond to the symmetric 220 and asymmetric and asymmetric stretching of acyl chain methylene at 2850 and 2886 cm -1 221 respectively, and the CH 3 methyl chain end symmetric stretch at 2935 cm -1 , which is thought Figure 3B shows that this separation is dominated by the negative loading of 335 two main lipid assignments ~2800-3000cm -1 indicating these are more intense in the control 336 WM samples (in black on the negative part of the PCA plot ( Figure 3A) ).
337
These preliminary results demonstrate that FTIR spectroscopy can be applied to analysis of 338 post-mortem WM tissue and successfully discriminate not only between lesion and control 339 WM but also between NAWM and control, without requiring any additional techniques. 
385
The analysis of post-mortem material, especially the comparison between NAWM and 386 normal WM can provide insights into molecular changes unveiling novel disease 387 mechanisms. And, although currently it cannot be applied for diagnostic purposes, due to the 388 constraints of obtaining brain tissue specimens, other patient specimen samples such as 389 CSF and blood might prove useful in the future to achieve a more rapid and accurate 390 diagnosis and prognosis for people with MS, much like has been recently reported for other 391 CNS diseases such as Alzheimer's.
392
Conclusion
393
The understanding of the underlying mechanism that lead to disease pathology and specially 394 disease progression is of great importance in neurodegenerative conditions, such as MS.
395
Spectroscopy techniques have the ability to unbiased characterisation of the biochemical 396 composition of post-mortem and clinical samples alike, thus able of providing insights into 397 the underlying changes occurring in tissue and biofluids (i.e. blood and CSF) which in turn 398 could be helpful to guide future in vitro research aimed at novel therapeutics.
399 Figure 1 . Mean FTIR spectra for four post-mortem samples analysed in the preliminary study: chronic lesion (blue), active lesion (red), NAWM (green) and control (black). All samples were subjected to FTIR analysis at the Focas Research Institute, DIT, using a Perkin Elmer Spotlight 400N FTIR imaging system, incorporating a liquid nitrogen cooled mercury cadmium telluride 16x1, 6.25µm pixel array detector, and acquired by the Spectral Image software. FTIR images from the tissue sections (10µm sections) mounted on CaF 2 slides were recorded over the range 4000-800 cm -1 in transmittance mode with a resolution of 4 cm -1 and interferometer speed of 1.0 cm -1 /second at continuously varying magnification.
The scans per pixel for background were 120 and, for images, 16 per pixel respectively.
Spectroscopic data analysis was carried out in Matlab, version R2013 (Mathworks, CA, USA) according to protocols developed and routinely used in-house at DIT. 
